Heart failure (HF) is currently considered a systemic multi-organ syndrome fundamentally driven by metabolic failure, and carnitines, a crucial metabolite in fatty acid metabolism, transport long-chain fatty acids into myocardial mitochondria to produce energy as a source of ATP generation [1] (Fig
These technologies may transform peptide delivery making treatments more effective and safer
Additionally, variations in genes encoding glutathione synthesis enzymes (GCLC, GCLM) can reduce baseline GSH production, though these are less common
Their most advanced oral program is orforglipron, a small-molecule GLP-1 receptor agonist that, unlike tirzepatide, is not a peptide and therefore does not face the same bioavailability challenges when taken orally
Repeated freeze-thaw cycles of the reconstituted solution should be avoided